Levbid Tablet, Extended Release
NDC Package 68220-115-10

11-digit billing NDC: 68220011510 · Billing unit: EA · 1 EA per package

Package Information

Levbid (hyoscyamine sulfate) tablets is levbid® is effective as adjunctive therapy in the treatment of peptic ulcer. This formulation utilizes a tablet, extended release delivery system. Marketed by Viatris Specialty Llc, this product is identified by NDC 68220-115.

Identification & Billing

NDC Package Code
68220-115-10
Package Description
1 TABLET, EXTENDED RELEASE in 1 BOTTLE
Product Code
11-Digit Billing Format
68220011510
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk
  • RxCUI: 1046770 - hyoscyamine sulfate 0.375 MG 12HR Extended Release Oral Tablet
  • RxCUI: 1046770 - 12 HR hyoscyamine sulfate 0.375 MG Extended Release Oral Tablet
  • RxCUI: 1046770 - hyoscyamine sulfate 0.375 MG 12 HR Extended Release Oral Tablet
  • RxCUI: 1046770 - hyoscyamine sulfate 375 MCG 12 HR Extended Release Oral Tablet
  • RxCUI: 1046771 - Levbid 0.375 MG 12HR Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Levbid
Non-Proprietary Name
Hyoscyamine Sulfate
Substance Name
Hyoscyamine Sulfate
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Levbid® is effective as adjunctive therapy in the treatment of peptic ulcer. It can also be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps. May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis, and acute enterocolitis. For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. Also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Levbid® is indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic; as a “drying agent” in the relief of symptoms of acute rhinitis; in the therapy of Parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis. May be used in the therapy of poisoning by anticholinesterase agents.

Regulatory & Marketing

Labeler Name
Viatris Specialty Llc
Product Type
Human Prescription Drug
Marketing Category
UNAPPROVED DRUG OTHER - An unapproved drug product in a marketing category that is not reflected on a particular list.
Start Marketing Date
12-01-2008
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68220-115-10 identifies a specific commercial package of 1 tablet, extended release in 1 bottle of Levbid, a human prescription drug labeled by Viatris Specialty Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This tablet, extended release is formulated for oral use and contains hyoscyamine sulfate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Viatris Specialty Llc on December 01, 2008. The current certification is valid through December 31, 2027.

How is this Viatris Specialty Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68220011510. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68220-115-10
11-Digit CMS (5-4-2)
68220-0115-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.